



---

20 April 2015  
Termiticide Standards Committee  
2015 Mid-Year ASPCRO Board Meeting Report

On behalf of the ASPCRO Termiticide Standards Committee, I respectfully submit the following report for the 2015 ASPCRO Mid-Year Board Meeting in Detroit, Michigan

Committee Chair: Mike Weyman (South Carolina)

Committee Members: Bobby Simoneaux (Gowon), John Campbell (Mississippi), George Saxton (Indiana), Steve Dwinell (Florida), Jonathon Berger (BASF), Jim Fredericks (NPMA), Carl Falco (Syngenta), Ryan Okey (South Carolina)

The Termiticide Standards Committee, TSC is working with the United States Environmental Protection Agency, EPA to review proposed efficacy policy and guidelines in order to update existing product performance standards and acceptable test conditions for all termite control products.

As you will recall at the ASPCRO annual meeting held in Atlanta the TSC heard a proposal to amend what historically has been the treatment method indicated for pre-construction termite treatments. Specifically, the proposal dealt with eliminating the overall treatment of the open slab area, OSA otherwise known as the broadcast treatment at the 1 gallon per 10 square feet, of the soil beneath the slab. The proposal made treatment beneath the slab limited to "critical areas". I believe the TSC has fulfilled our obligation in entertaining the aforementioned proposal. We have had multiple discussions and at times, lively debate between registrants, industry and researchers. As many of you are aware parallel to ASPCRO's TSC considering this proposal, NPMA decided to convene a panel of their own to further explore this paradigm shift. I believe I am on Terra Firma in stating sufficient efficacy data does not currently exist, nor does there seem to be funding to enter into the expansive EUP trials necessary to develop said data. As far as the TSC is concerned, as chair, I am intending to make a motion at the mid-year meeting, that this proposal be suspended as an action item. This suspension would remain in

place until such time as some entity comes forward with funding, to support the research, which would be required to substantiate such a deviation in current treatment practices.

Respectfully Submitted,

X

---

Mike Weyman  
Deputy Director

Mike Weyman, Chair TSC, Member-At-Large ASPCRO Board of Directors